Impact of percutaneous transluminal septal myocardial ablation on refractory paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. 2008

Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
First Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 1138603, Japan.

Atrial fibrillation is commonly observed in patients with hypertrophic obstructive cardiomyopathy. Episodes of paroxysmal atrial fibrillation are often torturous and limit the quality of life by causing congestive heart failure, transient hypotension, or bradycardia. Control of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy is considered to be important for symptomatic improvement and prevention of the development to chronic atrial fibrillation. The authors report on 3 patients with hypertrophic obstructive cardiomyopathy who suffered from paroxysmal atrial fibrillation despite receiving medical treatment using antiarrhythmic agents. However, after undergoing percutaneous transluminal septal myocardial ablation, the incidence of episodes became significantly less frequent. Percutaneous transluminal septal myocardial ablation is normally performed for attenuating left ventricular obstruction by reducing the systolic anterior motion of the mitral leaflet. However, in these patients, this procedure was also effective in preventing supraventricular arrhythmia, probably by improving left ventricular diastolic dysfunction, smooth blood inflow into the left ventricular, and decreasing the pressure stress against the left atrial wall.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001281 Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation,Familial Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Persistent Atrial Fibrillation,Atrial Fibrillation, Familial,Atrial Fibrillation, Paroxysmal,Atrial Fibrillation, Persistent,Atrial Fibrillations,Atrial Fibrillations, Familial,Atrial Fibrillations, Paroxysmal,Atrial Fibrillations, Persistent,Auricular Fibrillations,Familial Atrial Fibrillations,Fibrillation, Atrial,Fibrillation, Auricular,Fibrillation, Familial Atrial,Fibrillation, Paroxysmal Atrial,Fibrillation, Persistent Atrial,Fibrillations, Atrial,Fibrillations, Auricular,Fibrillations, Familial Atrial,Fibrillations, Paroxysmal Atrial,Fibrillations, Persistent Atrial,Paroxysmal Atrial Fibrillations,Persistent Atrial Fibrillations
D013614 Tachycardia, Paroxysmal Abnormally rapid heartbeats with sudden onset and cessation. Paroxysmal Reciprocal Tachycardia,Paroxysmal Reciprocal Tachycardias,Paroxysmal Tachycardia,Paroxysmal Tachycardias,Reciprocal Tachycardia, Paroxysmal,Reciprocal Tachycardias, Paroxysmal,Tachycardia, Paroxysmal Reciprocal,Tachycardias, Paroxysmal,Tachycardias, Paroxysmal Reciprocal
D013617 Tachycardia, Supraventricular A generic expression for any tachycardia that originates above the BUNDLE OF HIS. Supraventricular Tachycardia,Supraventricular Tachycardias,Tachycardias, Supraventricular

Related Publications

Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
January 2002, Chinese medical journal,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
September 2003, The Ceylon medical journal,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
March 2006, Zhonghua nei ke za zhi,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
August 2002, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
December 2008, Journal of medical ultrasonics (2001),
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
September 2003, Circulation journal : official journal of the Japanese Circulation Society,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
July 2006, Chinese medical journal,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
September 2002, Chinese medical journal,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
April 1999, The Thoracic and cardiovascular surgeon,
Yusuke Hosokawa, and Hitoshi Takano, and Tadaaki Ohno, and Morimasa Takayama, and Teruo Takano
July 1998, Japanese circulation journal,
Copied contents to your clipboard!